Core Insights - Legend Biotech Corporation announced long-term clinical data for CARVYKTI, showing a median progression-free survival (mPFS) of 50.4 months in triple-class-exposed relapsed/refractory multiple myeloma patients after a single infusion, marking one of the longest PFS outcomes for BCMA-targeted CAR-T therapy in this population [1][8][12] Group 1: Clinical Data and Efficacy - The CARTITUDE-1 and CARTITUDE-4 studies demonstrated that patients treated with CARVYKTI earlier in their treatment journey exhibited stronger immune fitness and a more immunocompetent tumor microenvironment, correlating with longer PFS [3][4][12] - At a median follow-up of 33.6 months, patients with standard-risk cytogenetics in the CARVYKTI arm achieved a 30-month PFS rate of 71.0%, compared to 43.2% in the standard-of-care arm [7][8] - Notably, all patients who achieved minimal residual disease (MRD)-negative complete response at 12 months following CARVYKTI infusion remained progression-free at 30 months [9] Group 2: Safety and Adverse Events - Among patients receiving CARVYKTI, cytokine release syndrome (CRS) occurred in 84% of cases, with a median time to onset of 7 days and resolution in 82% of patients [20][22] - Neurologic toxicities, including Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), occurred in 24% of patients, with a median time to onset of 10 days [25][28] - Hypogammaglobulinemia was reported in 36% of patients, with 93% experiencing laboratory IgG levels below 500 mg/dL after infusion [52][53] Group 3: Company Overview and Future Directions - Legend Biotech is a leader in cell therapy, particularly with CARVYKTI, which has been approved for treating relapsed or refractory multiple myeloma [64][65] - The company is focused on expanding patient access and therapeutic potential of CARVYKTI while driving innovation across its pipeline of cell therapy modalities [71]

Core Insights - Evaxion A/S has announced promising new data for its AML vaccine candidate, EVX-04, which shows strong T-cell responses and effective tumor growth prevention in preclinical models [1][5][10] - The data was presented at the American Society of Hematology Annual Meeting, highlighting the company's commitment to engaging with the scientific community and potential partners [2] - The AI-Immunology™ platform has enabled the identification of unique ERV tumor antigens, which are selectively expressed in tumors but absent in normal tissues, making them ideal targets for cancer vaccines [4][11] Company Overview - Evaxion is a clinical-stage TechBio company focused on developing AI-powered vaccines, particularly in the field of immunology [1][12] - The company utilizes its proprietary AI-Immunology™ platform to decode the human immune system and create novel immunotherapies for various diseases, including cancer [12] Product Details - EVX-04 is designed as an off-the-shelf therapeutic cancer vaccine for acute myeloid leukemia (AML), addressing a significant unmet medical need due to high mortality rates associated with the disease [10] - The vaccine targets multiple non-conventional ERV tumor antigens, which have been shown to elicit specific immune responses and prevent tumor growth in preclinical models [5][10] - The data-driven approach ensures broad tumor coverage, making EVX-04 applicable across various cancers where current immunotherapies are inadequate [6][10] Market Context - AML is characterized by high mortality rates and limited treatment options, with a median age of diagnosis at 68 years and a long-term survival rate of only 40% for younger patients undergoing intensive treatment [8][9] - Approximately 50% of AML patients are not fit for intensive treatment, relying on low-intensity chemotherapy, which has a poor three-year overall survival rate of only 25% [9]

Core Insights - Prelude Therapeutics has presented preclinical data on its JAK2V617F-selective JH2 inhibitors and mCALR-targeted degrader antibody conjugates at the American Society of Hematology (ASH) 67 Annual Meeting, highlighting their potential for disease modification in myeloproliferative neoplasms (MPNs) [1][2] JAK2V617F Inhibitor Program - PRT12396, a JAK2V617F-selective JH2 inhibitor, has shown robust preclinical activity, selectively inhibiting JAK2V617F while preserving wild-type JAK2 signaling, and demonstrated superior efficacy compared to ruxolitinib in multiple preclinical MPN models [2][4] - The company has completed GLP toxicology studies and plans to file an Investigational New Drug (IND) application and initiate a Phase 1 study in the first quarter of 2026 [3][4] - JAK2V617F mutation is present in approximately 95% of polycythemia vera (PV) patients, 60% of essential thrombocythemia (ET) patients, and 55% of myelofibrosis (MF) patients, making it a critical target for treatment [5][6] mCALR-targeted Degrader Antibody Conjugates - The company has introduced a novel mCALR-targeted degrader antibody conjugate (DAC) that delivers a CDK9 degrader payload selectively to malignant cells, demonstrating deep mutant-selective killing and sparing healthy hematopoietic cells [4][7] - mCALR is found in approximately 25-35% of patients with MF and ET, and recent clinical data has shown meaningful therapeutic benefits from mCALR-directed antibodies [7][8] Company Overview - Prelude Therapeutics is focused on developing innovative precision oncology medicines, with a pipeline that includes selective KAT6A degraders and JAK2V617F-selective JH2 inhibitors, aiming to address high unmet needs in cancer treatment [8]

Core Viewpoint - Ascentage Pharma presented promising results from a Phase II study of Lisaftoclax, a Bcl-2 selective inhibitor, for treating relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) at the ASH Annual Meeting, supporting its recent NDA approval in China [1][6][7] Company Overview - Ascentage Pharma Group International is a global biopharmaceutical company focused on developing novel therapies for unmet medical needs in cancer [16] - The company has a pipeline that includes inhibitors targeting key apoptotic pathway proteins and next-generation kinase inhibitors [16] Study Results - Lisaftoclax monotherapy showed a 62.5% objective response rate (ORR) in heavily pretreated BTK-refractory R/R CLL/SLL patients, with a median progression-free survival of 23.89 months [6][11] - Among 77 enrolled patients, 42.9% had chromosomal complex karyotype, 39% had del(17p)/TP53 mutation, and 53.2% had unmutated IGHV, indicating a high-risk patient population [3][13] - The study reported no tumor lysis syndrome (TLS) and a manageable safety profile, with frequent grade ≥3 treatment-related adverse events being hematologic toxicities [14][6] Clinical Significance - The results highlight Lisaftoclax's potential as a new treatment option for patients with high-risk CLL/SLL, addressing an urgent clinical need for effective therapies [5][7] - The study's findings suggest that even in ultra-high-risk patients, Lisaftoclax can achieve deep and durable responses, with 21.8% of patients achieving minimal residual disease (MRD) negativity in peripheral blood [11][15] Future Directions - Ascentage Pharma is conducting four global registrational Phase III studies for Lisaftoclax in various indications, including CLL/SLL, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS) [4][18] - The company aims to accelerate clinical programs to provide safe and effective therapies to patients globally [7]

Core Insights - Cogent Biosciences announced complete results from the SUMMIT clinical trial of bezuclastinib, showing significant improvements in patients with nonadvanced systemic mastocytosis (NonAdvSM) [1][2] - Bezuclastinib is expected to be a best-in-class treatment option, with a New Drug Application (NDA) submission to the FDA planned for December 2025 [2][6] SUMMIT Trial Data - The trial involved 118 patients receiving bezuclastinib and 60 receiving placebo, with a focus on those with moderate-to-severe symptoms despite best supportive care [3][4] - At 24 weeks, bezuclastinib showed a mean change in Total Symptom Score (TSS) of -24.3% compared to -15.4% for placebo, with a p-value of <0.001 [5] - 34.3% of patients on bezuclastinib achieved a ≥50% reduction in TSS, compared to 18.1% on placebo [5] Symptomatic and Objective Improvements - Bezuclastinib demonstrated significant improvements across 11 individual symptoms and objective measures of disease, including serum tryptase levels [6][7] - At 48 weeks, 87.4% of patients achieved a ≥50% reduction in serum tryptase levels, and 75.6% showed a ≥50% reduction in bone marrow mast cells [7] Safety Profile - The majority of treatment-emergent adverse events (TEAEs) were low grade, with 98.3% in the bezuclastinib arm versus 88.3% in the placebo arm [9] - Common TEAEs included hair color change (69.5% in bezuclastinib vs. 5.0% placebo) and nausea (22.0% in bezuclastinib vs. 13.3% placebo) [9] Future Plans - Cogent plans to present longer-term follow-up data from the SUMMIT trial at a scientific meeting in Q1 2026 [10] - An investor conference call is scheduled for December 8, 2025, to discuss the additional data from the SUMMIT trial [11]

Core Insights - Genmab A/S announced updated results from two clinical trials evaluating epcoritamab-bysp for treating diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), showing high overall response rates (ORR) and promising survival outcomes [2][8][11]. Trial Results Summary - In the EPCORE NHL-2 trial, Arm 8 demonstrated an ORR of 93% and a complete response (CR) rate of 86% in elderly patients with newly diagnosed DLBCL, with 79% of responders maintaining their response at two years [4][6]. - Arm 1 of the same trial showed an ORR of 98% and an 85% CR rate in patients with newly diagnosed DLBCL, with 74% of CRs ongoing after a median follow-up of 44.2 months [7][9]. - The EPCORE DLBCL-3 trial reported a 73% ORR and 62% CR rate in elderly patients unable to receive standard chemotherapy, with 54% progression-free and 65% alive at one year [3][14]. Safety Profile - Treatment-emergent adverse events (TEAEs) were consistent with previous studies, with Grade ≥3 infections occurring in 32% of patients, primarily in the first six cycles [5][10]. - Serious TEAEs included Grade 5 events, but no new serious infections were reported post-treatment [10][15]. Epcoritamab Overview - Epcoritamab is a bispecific antibody designed to engage T-cells and target B-cells, showing potential as a core therapy for various B-cell malignancies [23][24]. - The drug has received regulatory approval in certain lymphoma indications and is co-developed by Genmab and AbbVie [24][25]. Industry Context - DLBCL is the most common type of non-Hodgkin lymphoma, accounting for 25-30% of cases, with approximately 25,000 new cases diagnosed annually in the U.S. [17]. - Follicular lymphoma, accounting for 20-30% of NHL cases, is considered incurable with current therapies, highlighting the need for effective treatment options [18].

Core Insights - Adaptive Biotechnologies Corporation is showcasing the increasing interventional use of its clonoSEQ test at the 67th American Society of Hematology Annual Meeting, with 90 abstracts featuring clonoSEQ data, including 17 that demonstrate its role in guiding clinical actions for blood cancer patient care [1][9] Group 1: Clinical Applications and Studies - The phase II EndRAD study supports the use of next-generation sequencing (NGS) measurable residual disease (MRD) status prior to allogeneic hematopoietic cell transplantation (HCT) to select non-total body irradiation (TBI) conditioning approaches, showing excellent event-free and overall survival in 51 NGS MRD negative patients [2][3] - Across hematologic malignancies, clonoSEQ MRD status is utilized by healthcare providers to guide clinical decisions, with presentations demonstrating its application in tailoring treatment intensity and duration [3][9] - A phase III AURIGA study involving 200 newly diagnosed multiple myeloma (MM) patients showed that deep MRD responses correlated with improved progression-free survival, and intensified maintenance in MRD-positive patients post-transplant doubled MRD negativity rates [7] Group 2: Abstracts and Research Findings - A total of 32 abstracts on multiple myeloma will be presented, focusing on MRD assessment of treatment response and real-world data linking MRD status to clinical outcomes [7] - In non-Hodgkin lymphoma (NHL), 15 abstracts will explore MRD to understand treatment response depth and guide therapy, including a study on de-escalating therapy in frail older adults with diffuse large B-cell lymphoma (DLBCL) [7] - Data from a phase II study of 80 previously untreated chronic lymphocytic leukemia (CLL) patients indicated that time-limited therapy achieved deep and durable remissions based on MRD assessment [8] Group 3: clonoSEQ Overview - clonoSEQ is the first FDA-cleared in vitro diagnostic test for detecting and tracking MRD in patients with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, and is also available for other lymphoid cancers as a CLIA-validated laboratory developed test [10][11] - The test identifies and quantifies DNA sequences in malignant cells, detecting one cancer cell in one million healthy cells, providing standardized and sensitive results that inform treatment decisions and predict outcomes [11]

Core Insights - Arvinas, Inc. announced preclinical data for ARV-393 in combination with glofitamab, showing significant tumor growth inhibition in a model of diffuse large B-cell lymphoma (DLBCL) [1][3] - The company plans to initiate a Phase 1 clinical trial for this combination approach in 2026, aiming to provide a chemotherapy-free treatment option for patients with DLBCL [2][3] Group 1: Preclinical Data and Mechanism - The combination of ARV-393 (3 mg/kg) and glofitamab (0.15 mg/kg) achieved 81% tumor growth inhibition (TGI) with concomitant dosing and 91% TGI with sequential dosing, compared to 38% for ARV-393 alone and 36% for glofitamab alone [5] - At a higher dose of ARV-393 (6 mg/kg), the combination showed increased tumor regressions, with 10 out of 10 mice responding to concomitant dosing [5] - RNA sequencing indicated that ARV-393 upregulated CD20 expression and genes promoting interferon signaling, while downregulating proliferation-associated gene sets, contributing to the observed antitumor activity [5] Group 2: Clinical Development Plans - Arvinas is currently evaluating ARV-393 in a Phase 1 clinical trial for relapsed/refractory non-Hodgkin lymphoma and plans to share clinical data from this trial at a medical congress in 2026 [3] - The addition of a glofitamab combination cohort in the ongoing Phase 1 clinical trial of ARV-393 is planned for 2026 [3] Group 3: Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing protein degradation therapies through its PROTAC platform, targeting various diseases including B-cell lymphomas [4][6] - The company is also advancing other investigational drugs targeting neurodegenerative disorders and mutated cancers [6]

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study interim analysis Totality of data demonstrates that greater TGF-β inhibition, observed at 1500mg of ficerafusp alfa, drives deeper tumor responses that translate to more durable outcomes for patients Pivotal FORTIFI-HN01 optimal dose declaration expected in first quarter 2026 Company to host conference call and ...

Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Durable for up to 20 Months Patients Required a Median of One Cell Collection Cycle and Experienced Rapid Neutrophil and Platelet Engraftment Safety Profile Remained Consistent with Busulfan Conditioning, Autologous Hematopoietic Stem Cell Transplantation and Underlying SCD CAMBRIDGE, Mass., Dec. 06, 2 ...